Research into immunotherapy against cancer typically focuses on better recognition of cancer cells by the body's own immune ...

Doctors group B-cell lymphomas based on ... with polyangiitis (formerly known as Wegener's granulomatosis) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Chronic lymphocytic ...

If CLL progresses to the point where treatment ... inhibitors and antiapoptotic protein B cell lymphoma 2 (BCL2) inhibitors. These medications target cancer cells with specific mutations.

Immunotherapy research primarily focuses on improving the body’s immune system’s recognition of cancer cells. However, ...

Ibrutinib remains a key treatment for relapsed chronic lymphocytic leukemia (CLL), but findings suggest that combining it ...

During a Case-Based Roundtable® event, Ryan W. Jacobs, MD, discussed a patient who received 2 prior lines of therapy for ...

The following is a summary of "BCL-2 dependence is a favorable predictive marker of response to therapy for chronic ...

Fred Locke, MD, Moffitt Cancer Center, explains why this hematologic cancer is such an attractive target for chimeric antigen ...

complex have emerged as major markers for prognostic classification of B-cell chronic lymphocytic leukemia (B-CLL). In particular, the absence of somatic mutations within the immunoglobulin ...

The degree of chronic lymphocytic leukemia (CLL) B-cell antigen receptor (BCR) binding to myosin-exposed apoptotic cells (MEACs) correlates with worse patient outcomes, suggesting a link to ...

Research into immunotherapy against cancer typically focuses on better recognition of cancer cells by the body's own immune system. Researchers at Amsterdam UMC and Moffitt Cancer Center have taken a ...